NASDAQ:ENVB

Enveric Biosciences Q2 2025 Earnings Results & Report

Enveric Biosciences logo
$1.44 -0.08 (-4.95%)
Closing price 11/16/2026 04:00 PM Eastern
Extended Trading
$1.44 0.00 (0.00%)
As of 11/16/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Enveric Biosciences beat analyst earnings expectations in its Q2 2025 results, released August 14, 2025. The company reported EPS of -$11.64 versus the -$63.00 consensus estimate.

Earnings Announcement Details

Quarter
Q2 2025
Report Date
Time
Before Market Opens

Enveric Biosciences EPS Results

Actual EPS
-$11.64
Consensus EPS
-$63.00
Beat/Miss
Beat by +$51.36
One Year Ago EPS
N/A
EPS Beat Rate
4 of last 4 quarters

Enveric Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Enveric Biosciences Q2 2025 Earnings FAQ

Enveric Biosciences (NASDAQ:ENVB) reported earnings of -$11.64 per share for Q2 2025, beating the consensus estimate of -$63.00. The report was announced on Thursday, August 14, 2025.

Enveric Biosciences Earnings Headlines

Pentagon magnet restrictions take effect January 1, 2027
A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel
See More Enveric Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enveric Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enveric Biosciences and other key companies, straight to your email.

About Enveric Biosciences

Enveric Biosciences (NASDAQ:ENVB) is a biotechnology company developing small-molecule treatments for mental health conditions. Its research focuses on neuroplastogens—compounds designed to promote changes in neural connections—with potential applications in disorders such as depression and anxiety.

The company uses its Psybrary platform, a library of compounds inspired by psychedelic molecules, to identify and develop therapeutic candidates. Its programs are in development, and the company’s work is focused on research rather than marketed medicines.

Enveric expanded into psychedelic-inspired drug discovery through its 2021 acquisition of MagicMed Industries. It is headquartered in Naples, Florida.

View Enveric Biosciences Profile